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Following publication of our article [1] we noticed an error in
the stated dose of methotrexate within the section ‘Results’,
in the paragraph ‘Demographics and patient characteristics
at study entry’.
In this paragraph, it is stated that two patients were receiving
20 mg/day methotrexate. This should read 20 mg/week
methotrexate. 
The paragraph should therefore read as follows:
A total of 14 Caucasian patients (13 females and 1 male; 23
to 53 years old, median age 40 years) were enrolled. At study
entry, the patients had been initially diagnosed with SLE 1 to
19 years (median 10 years) earlier and were receiving
corticosteroids (n = 13, 1 to 12 mg/day prednisolone) plus
immunosuppressives (n = 11, including 50 to 200 mg/day
azathioprine, n = 9; 20 mg/week methotrexate, n = 2; 2 g/day
mycophenalate mofetil, n = 1), and antimalarials (n = 6, 200
to 600 mg/day hydroxychloroquine). All patients had positive
ANA at study entry (titers of 80:1 to 5,120:1), and 5 patients
(36%) had positive anti-dsDNA antibody levels (>10 U/ml).
Ten patients (71%) had ESR values that were elevated
(>15 mm/h) and 4 patients (29%) had raised CRP levels
(>0.5 mg/dl), while only 3 patients (21%) had C3 levels that
were borderline low or decreased (<90 mg/dl), and no
patient had positive direct Coombs' or serum haptoglobulin
levels elevated above borderline.
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